# Antheia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antheia

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.antheia.bio/
- Total disclosed funding: $233M
- Latest round: Debt (Oct 19, 2026)
- Investors on record: 11

## About

Antheia, Inc., based in the US, develops innovative biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) that enhance pharmaceutical supply chains and address modern medical needs.Founded in 2015 and headquartered in Menlo Park, US, Antheia, Inc. specializes in biosynthetic pharmaceutical production. The company's founders include Christina Smolke, Kristy Hawkins, and Lauren Zatulove. Recently, the company raised USD 17.000 mn in a funding round on July 19, 2024, led by In-Q-Tel and Echo Investment Capital, with participation from returning investor Viking Global Investors. In June 2025, Antheia, Inc. raised USD 55 million in series C funding co-led by new investors EDBI and Global Health Investment Corporation, with participation from other new investors Athos Service and Federov. Returning investors Civilization Ventures, In-Q-Tel, S-Cubed Capital, Sherpalo Ventures, and Viking Global Investors also participated in the round. This funding will support the company's growth initiatives. Antheia specializes in the production of biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) designed to address the complexities and demands of modern medicine. Leveraging synthetic biology, the company offers an innovative platform that enhances the reliability, efficiency, and sustainability of pharmaceutical supply chains. Antheia’s solutions aim to mitigate drug shortages and the inefficiencies associated with traditional agricultural sourcing, which is often vulnerable to climate variability and other agricultural challenges. The company's products serve a diverse client base, including pharmaceutical manufacturers and healthcare providers, focused primarily on the North American and European markets. By transitioning to biomanufacturing in contained fermentation environments, Antheia ensures consistent yields and supports more equitable access to essential medicines.Antheia generates revenue primarily through B2B transactions with pharmaceutical manufacturers and healthcare partners. The company’s business model is structured around long-term partnerships and collaborations, particularly in biomanufacturing, which aligns with the growing demand for reliable pharmaceutical ingredients. Clients engage in contractual agreements covering the supply of biosynthetic KSMs and APIs, reflecting the strategic importance of these products in the manufacturing of essential medications. Specific pricing structures are customized based on contract terms and volume of products ordered, ensuring financial arrangements meet the unique needs of each client. Through these partnerships, Antheia positions itself as a pivotal contributor to the pharmaceutical industry, fostering innovation and sustainability in drug development and production.In July 2024, Antheia, Inc. raised USD 17.000 mn in venture funding to support the development of new products and expansion into additional geographic markets. The funding will be used to enhance its current offerings and facilitate entry into new markets within North America and Europe by the end of 2025. This strategic approach aims to strengthen Antheia's role in the pharmaceutical industry while ensuring a reliable supply of essential medicines. The company will use the funding to commercialize its first product, launch additional biosynthetic pharmaceutical ingredients, expand U.S. manufacturing, and support new innovation programs in Singapore and Asia.

## Funding rounds

- Debt, Oct 19, 2026, $80M — U.S. Department of Defense's Office of Strategic Capital
- Series C, Jan 27, 2026, $24M — Athos Service, America's Frontier Fund, Global Health Investment Corporation
- Series C, Jun 3, 2025, $56M — Viking Global Investors, SG Growth Capital, In-Q-Tel, Sherpalo Ventures, S-Cubed Capital, Athos Service, Civilization Ventures, Global Health Investment Corporation
- Series B, Jun 30, 2021, $73M — Viking Global Investors, Sherpalo Ventures, Hillspire

## Investors

- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B, Series C
- Sherpalo Ventures (https://capitalatlas.ai/funds/sherpalo-ventures) — Series B, Series C
- Hillspire — Series B
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series C
- In-Q-Tel (https://capitalatlas.ai/funds/in-q-tel) — Series C
- S-Cubed Capital — Series C
- Athos Service — Series C
- Civilization Ventures (https://capitalatlas.ai/funds/civilization-ventures) — Series C
- Global Health Investment Corporation (https://capitalatlas.ai/funds/global-health-investment-corporation) — Series C
- America's Frontier Fund (https://capitalatlas.ai/funds/america-s-frontier-fund) — Series C
- U.S. Department of Defense's Office of Strategic Capital — Debt